[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Generic_Tina Tina Banerjee Tina Banerjee posts on X about core, china, future, $4523t the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1511682976639119365/interactions)  - X Week XXX -XX% - X Month XXX -XX% - X Months XXXXX +91% - X Year XXXXXX +276% ### Mentions: X [#](/creator/twitter::1511682976639119365/posts_active)  - X Week XX +5% - X Month XX -XXXX% - X Months XXX +52% - X Year XXX +229% ### Followers: XX [#](/creator/twitter::1511682976639119365/followers)  - X Week XX no change - X Month XX -XXXX% - X Months XX +33% - X Year XX +46% ### CreatorRank: undefined [#](/creator/twitter::1511682976639119365/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) XXXX% [countries](/list/countries) XXXX% [technology brands](/list/technology-brands) XXXX% [stocks](/list/stocks) XXXX% **Social topic influence** [core](/topic/core) 9.52%, [china](/topic/china) 9.52%, [future](/topic/future) 9.52%, [$4523t](/topic/$4523t) 4.76%, [cro](/topic/cro) 4.76%, [$100m](/topic/$100m) 4.76%, [$325m](/topic/$325m) 4.76%, [$420450m](/topic/$420450m) 4.76%, [samsung](/topic/samsung) 4.76%, [$4516t](/topic/$4516t) XXXX% ### Top Social Posts Top posts by engagements in the last XX hours "Innovent Biologics reports 1H25 results with XX% revenue growth and maiden net profit driven by core oncology product Tyvyt. Mazdutide approval in China along witth Tyvyt to drive future growth" [X Link](https://x.com/Generic_Tina/status/1973547314955587688) 2025-10-02T00:35Z XX followers, XX engagements "Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus. PharmaEssentia filed label expansion of Besremi in US" [X Link](https://x.com/Generic_Tina/status/1984781327884050659) 2025-11-02T00:35Z XX followers, XXX engagements "Innovent Biologics reports 1H25 results with XX% revenue growth and maiden net profit driven by core oncology product Tyvyt. Mazdutide approval in China along witth Tyvyt to drive future growth" [X Link](https://x.com/Generic_Tina/status/1992968672974148080) 2025-11-24T14:48Z XX followers, XX engagements "in 3Q25 SKBP reported U.S. sales of Xcopri exceeding $100M for the second time. During 9M25 U.S. sales of Xcopri reached $325M with full-year 2025 guidance remaining at $420450M" [X Link](https://x.com/Generic_Tina/status/1993478610905342352) 2025-11-26T00:35Z XX followers, XX engagements "Simcere stuck license pact with Vigonvita. Kelun Bio inked partnership with Crescent Biopharma. Samsung Biologics is acquiring land for third campus. Biocon settled with Amgen for Prolia biosimilar" [X Link](https://x.com/Generic_Tina/status/1997464896636932332) 2025-12-07T00:35Z XX followers, XX engagements "Nippon Shinyaku and Capricor announce positive Phase X results for Deramiocel with potential FDA approval and commercialization on the horizon. Near term concerns with Viltepso remain" [X Link](https://x.com/Generic_Tina/status/1997827292417163681) 2025-12-08T00:35Z XX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Generic_Tina Tina BanerjeeTina Banerjee posts on X about core, china, future, $4523t the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Social category influence finance XXXX% countries XXXX% technology brands XXXX% stocks XXXX%
Social topic influence core 9.52%, china 9.52%, future 9.52%, $4523t 4.76%, cro 4.76%, $100m 4.76%, $325m 4.76%, $420450m 4.76%, samsung 4.76%, $4516t XXXX%
Top posts by engagements in the last XX hours
"Innovent Biologics reports 1H25 results with XX% revenue growth and maiden net profit driven by core oncology product Tyvyt. Mazdutide approval in China along witth Tyvyt to drive future growth"
X Link 2025-10-02T00:35Z XX followers, XX engagements
"Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus. PharmaEssentia filed label expansion of Besremi in US"
X Link 2025-11-02T00:35Z XX followers, XXX engagements
"Innovent Biologics reports 1H25 results with XX% revenue growth and maiden net profit driven by core oncology product Tyvyt. Mazdutide approval in China along witth Tyvyt to drive future growth"
X Link 2025-11-24T14:48Z XX followers, XX engagements
"in 3Q25 SKBP reported U.S. sales of Xcopri exceeding $100M for the second time. During 9M25 U.S. sales of Xcopri reached $325M with full-year 2025 guidance remaining at $420450M"
X Link 2025-11-26T00:35Z XX followers, XX engagements
"Simcere stuck license pact with Vigonvita. Kelun Bio inked partnership with Crescent Biopharma. Samsung Biologics is acquiring land for third campus. Biocon settled with Amgen for Prolia biosimilar"
X Link 2025-12-07T00:35Z XX followers, XX engagements
"Nippon Shinyaku and Capricor announce positive Phase X results for Deramiocel with potential FDA approval and commercialization on the horizon. Near term concerns with Viltepso remain"
X Link 2025-12-08T00:35Z XX followers, XX engagements
/creator/x::Generic_Tina